News

Medical Xpress6d
Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients
Early transcatheter aortic valve replacement (TAVR) in asymptomatic severe aortic stenosis reduces the risk of death, stroke, and heart failure hospitalization compared to clinical surveillance.
U.S. News & World Report2d
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis By Lori Solomon HealthDay ReporterMONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...
Healio7d
FDA approves first TAVR platform to treat severe asymptomatic aortic stenosis
A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.
TCTMD7d
FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis
Asymptomatic patients with severe aortic stenosis can now undergo transcatheter aortic valve replacement, thanks to the US Food and Drug Administration’s approval of the new indication for the balloon ...
KTBS3d
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
In the EARLY TAVR trial, which informed the approval, patients with asymptomatic severe aortic stenosis were randomly assigned to either TAVR or watchful waiting. During a median follow-up of 3.8 ...
Yahoo Finance6d
FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients
platform for the treatment of patients with asymptomatic severe aortic stenosis (AS), expanding its use to a broader population. Marking a first approval for a TAVR system’s use in asymptomatic ...
KTEN3d
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
MONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe ...